An early case report showed that treatment with SCD in two COVID-19 patients with severe ARDS resulted in significant reductions in inflammatory markers, including procalcitonin, D-dimer, LDH, ferritin, CRP, and IL-6 (63). This evidence concerns the gene CRP and acute respiratory distress syndrome.